VistaGen Therapeutics Inc... (VTGN)
NASDAQ: VTGN
· Real-Time Price · USD
2.36
0.00 (0.00%)
At close: Jun 17, 2025, 3:59 PM
2.28
-3.39%
After-hours: Jun 17, 2025, 07:34 PM EDT
0.00% (1D)
| Bid | 2.28 |
| Market Cap | 68.11M |
| Revenue (ttm) | 698.3K |
| Net Income (ttm) | -47.3M |
| EPS (ttm) | -1.48 |
| PE Ratio (ttm) | -1.59 |
| Forward PE | -1.32 |
| Analyst | n/a |
| Ask | 2.43 |
| Volume | 238,346 |
| Avg. Volume (20D) | 132,493 |
| Open | 2.33 |
| Previous Close | 2.36 |
| Day's Range | 2.28 - 2.41 |
| 52-Week Range | 1.90 - 4.21 |
| Beta | 0.69 |
About VTGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VTGN
Website n/a
Earnings Surprise
VistaGen Therapeutics has released their quartely earnings
on Jun 17, 2025:
Next Earnings Release
VistaGen Therapeutics Inc. is scheduled to release its earnings on Jun 17, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
20 hours ago · seekingalpha.com
Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call TranscriptVistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2025 Earnings Conference Call June 17, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Mark Adrian McPartland - ...
22 hours ago · businesswire.com
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate UpdateSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
3 months ago · businesswire.com
Vistagen to Present at the 2025 Anxiety and Depression Association ConferenceSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize...